Clinical Scorecard: Depth of Invasion and Contralateral Nodal Disease in Lateralized Oral Tongue Squamous Cell Carcinoma
At a Glance
Category
Detail
Condition
Contralateral nodal disease in lateral oral tongue squamous cell carcinoma
Key Mechanisms
The study aimed to assess the association between depth of invasion and contralateral nodal disease, defined as disease in the opposite neck at presentation or recurrence after treatment.
Target Population
Patients with oral tongue SCC arising in the lateral tongue and treated with surgical resection at one tertiary academic center from 1998 through 2021; patients with distant metastasis at presentation or incomplete clinical or pathological information were excluded.
Care Setting
Single-center retrospective cohort study.
Key Highlights
The study aimed to assess the association between depth of invasion and contralateral nodal disease in lateralized oral tongue SCC.
Contralateral nodal disease was defined as disease in the opposite neck at presentation or recurrence after treatment.
DOI was measured according to the AJCC eighth-edition method; two anatomic pathologists reassessed specimens, and patients with differing measurements were excluded.
The supplied excerpt does not report this study's results. Its introduction cites a prior institutional analysis reporting DOI ≥6 mm as a possible threshold associated with increased contralateral nodal disease risk.
Guideline-Based Recommendations
Diagnosis
The study defined DOI according to the AJCC eighth-edition method: measure perpendicularly from the reference plane of the normal adjacent basement membrane to the deepest point of invasion.
Contralateral nodal disease was generally established by positive final pathology; the excerpt also describes imaging suspicion followed by biopsy confirmation in the metastatic setting.
Management
The introduction states that elective or therapeutic neck dissection remains standard care for nodal disease in oral tongue SCC.
The excerpt does not establish a DOI threshold for contralateral neck management.
Monitoring & Follow-up
The study recorded follow-up duration and evaluated contralateral neck recurrence as an outcome.
The excerpt is truncated during its description of how contralateral nodal disease was determined in the metastatic setting; do not add further monitoring details.
Risks
The introduction states that cervical lymph node metastasis is an independent predictor of survival in head and neck cancer and that extranodal extension is associated with further survival decline.
The supplied excerpt does not report this study's contralateral nodal disease rates or DOI-associated risk estimates.
Patient & Prescribing Data
Retrospective cohort of patients with lateral oral tongue SCC treated primarily with surgical resection; patients with distant metastasis at presentation or incomplete clinical or pathological information were excluded.
Surgical resection was the primary treatment for all included patients. Most underwent ipsilateral neck dissection; five underwent bilateral dissection because of evident nodal disease on preoperative imaging or a primary tumor nearing the midline.
Clinical Best Practices
The study used the AJCC eighth-edition DOI measurement method.
Interpret the supplied material as a single-center retrospective study excerpt; it does not provide this study's findings or establish a contralateral neck DOI cutoff.
Distinguish contralateral nodal disease present at presentation from disease identified as recurrence after treatment.
CAR T Vision aims to widen access to cell therapy by expanding community-based delivery, easing operational barriers, and building sustainable funding models
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.
